Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial

2021142 citationsJournal Articlegold Open Access

Authors

Mariano Duarte · University of Buenos Aires

Facundo Pelorosso · Asociación por los Derechos Civiles

Liliana Nicolosi · Hospital Británico de Buenos Aires

María Victoria Salgado · Center for the Study of State and Society

Héctor Vetulli · Sanatorio Otamendi y Miroli

Analía Aquieri · University of Buenos Aires

Francisco Azzato

Abstract

Our study suggests that the ARB telmisartan, a widely used antihypertensive drug, is safe and could reduce morbidity and mortality in hospitalized patients infected with SARS -CoV-2 by anti-inflammatory effects. Further studies employing telmisartan are needed for confirmation of our results and to define its true therapeutic value as a tool against Covid-19.

Topics & Keywords

COVID-19 Clinical Research Studies Long-Term Effects of COVID-19 Respiratory Support and Mechanisms

UN Sustainable Development Goals

Peace, Justice and strong institutions

Publication Details

Published in: EClinicalMedicine

Volume 37, pp. 100962-100962

DOI: 10.1016/j.eclinm.2021.100962

Field-Weighted Citation Impact: 8.52